Keros Therapeutics (KROS) Leases (2019 - 2025)
Historic Leases for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $17.5 million.
- Keros Therapeutics' Leases fell 1190.54% to $17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year decrease of 1190.54%. This contributed to the annual value of $19.3 million for FY2024, which is 2554.45% up from last year.
- As of Q3 2025, Keros Therapeutics' Leases stood at $17.5 million, which was down 1190.54% from $18.1 million recorded in Q2 2025.
- In the past 5 years, Keros Therapeutics' Leases ranged from a high of $19.8 million in Q3 2024 and a low of $447000.0 during Q3 2022
- Its 5-year average for Leases is $10.1 million, with a median of $15.0 million in 2024.
- In the last 5 years, Keros Therapeutics' Leases crashed by 3614.29% in 2022 and then skyrocketed by 340536.91% in 2023.
- Quarter analysis of 5 years shows Keros Therapeutics' Leases stood at $1.1 million in 2021, then surged by 1343.3% to $15.4 million in 2022, then decreased by 0.43% to $15.3 million in 2023, then grew by 25.54% to $19.3 million in 2024, then fell by 9.29% to $17.5 million in 2025.
- Its last three reported values are $17.5 million in Q3 2025, $18.1 million for Q2 2025, and $18.7 million during Q1 2025.